

AMENDMENTS TO THE CLAIMS

Claims 1-7 (Canceled).

Claim 8 (Currently Amended): A method for increasing the ~~eytostatic and cytotoxic~~ cytostatic or cytotoxic effects on tumor cells, and decreasing the cytotoxic effect on normal leucocytes of an anticancer medicinal product selected among platinum derivatives, ~~5-fluorouracil, and taxanes~~, wherein said method comprises administering to a patient treated with said anticancer medicinal product, an antitumoral and leukocyte-protecting amount of mangafodipir.

Claim 9 (Canceled)

Claim 10 (Previously Presented) The method of claim 8, wherein the amount of mangafodipir administered to said patient is from 1 to 100mg/kg/day.

Claim 11 (Currently Amended) A pharmaceutical composition comprising mangafodipir and an antitumor agent selected among platinum derivatives, ~~5-fluorouracil and taxanes~~.